Carnegie Investment Counsel Has $6.54 Million Stock Position in Novo Nordisk A/S $NVO

Carnegie Investment Counsel lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 27.3% during the first quarter, Holdings Channel reports. The firm owned 178,029 shares of the company’s stock after selling 67,020 shares during the period. Carnegie Investment Counsel’s holdings in Novo Nordisk A/S were worth $6,543,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of NVO. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter worth $25,000. WealthCollab LLC increased its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $28,000. Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S during the fourth quarter valued at about $29,000. Finally, Maseco LLP acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NVO. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Wolfe Research assumed coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Finally, Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Up 0.0%

Shares of NYSE:NVO opened at $49.49 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock’s 50-day moving average is $45.57 and its 200-day moving average is $45.86. The company has a market cap of $220.96 billion, a P/E ratio of 11.62, a P/E/G ratio of 4.51 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.